loadpatents
name:-0.010962963104248
name:-0.020539999008179
name:-0.00062990188598633
Bedin; Frederic Patent Filings

Bedin; Frederic

Patent Applications and Registrations

Patent applications and USPTO patent grants for Bedin; Frederic.The latest application filed is for "method and kit for determining the probability that a patient will develop a severe case of dengue".

Company Profile
0.16.16
  • Bedin; Frederic - Lyons FR
  • BEDIN; Frederic - Lyon FR
*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Patent Activity
PatentDate
Method for the in vitro prediction of the probability of a patient developing severe dengue, based on a blood sample
Grant 10,823,732 - Bedin November 3, 2
2020-11-03
Method and kit for determining the probability that a patient will develop a severe case of dengue
Grant 10,309,965 - Bedin , et al.
2019-06-04
Method and kit for determining the probability that a patient will develop a severe case of dengue
Grant 10,281,470 - Bedin , et al.
2019-05-07
Method And Kit For Determining The Probability That A Patient Will Develop A Severe Case Of Dengue
App 20180196046 - BEDIN; Frederic ;   et al.
2018-07-12
Method And Kit For Determining The Probability That A Patient Will Develop A Severe Case Of Dengue
App 20180196045 - BEDIN; Frederic ;   et al.
2018-07-12
Method For The In Vitro Prediction Of The Probability Of A Patient Developing Severe Dengue, Based On A Blood Sample
App 20180120316 - BEDIN; Frederic
2018-05-03
Method and kit for determining the probability that a patient will develop a severe case of dengue
Grant 9,945,857 - Bedin , et al. April 17, 2
2018-04-17
Method and kit for determining the probability that a patient will develop a severe case of dengue
Grant 9,933,426 - Bedin , et al. April 3, 2
2018-04-03
Method for the in vitro prediction of the probability of a patient developing severe dengue, based on a blood sample
Grant 9,863,948 - Bedin January 9, 2
2018-01-09
Process for the detection and early serotyping of the dengue virus
Grant 9,778,260 - Bedin , et al. October 3, 2
2017-10-03
Method And Kit For Determining The Probability That A Patient Will Develop A Severe Case Of Dengue
App 20160363590 - BEDIN; Frederic ;   et al.
2016-12-15
Method And Kit For Determining The Probability That A Patient Will Develop A Severe Case Of Dengue
App 20160363589 - Bedin; Frederic ;   et al.
2016-12-15
Method For The In Vitro Prediction Of The Probability Of A Patient Developing Severe Dengue, Based On A Blood Sample
App 20150126386 - Bedin; Frederic
2015-05-07
Process For The Detection And Early Serotyping Of The Dengue Virus
App 20140051067 - Bedin; Frederic ;   et al.
2014-02-20
Isolated multiple sclerosis (MS)-associated retrovirus (MSRV) nucleic acids corresponding to the gag region
Grant 8,088,910 - Paranhos-Baccala , et al. January 3, 2
2012-01-03
Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes
Grant 7,932,350 - Perron , et al. April 26, 2
2011-04-26
Retroviral Nucleic Material And Nucleotide Fragments, In Particular Associated With Multiple Sclerosis And/or Rheumatoid Arthritis, For Diagnostic, Prophylactic And Therapeutic Uses
App 20100285448 - PARANHOS-BACCALA; Glaucia ;   et al.
2010-11-11
Multiple sclerosis-associated retroviral (MSRV) nucleic acids corresponding to the Env region
Grant 7,771,927 - Paranhos-Baccala , et al. August 10, 2
2010-08-10
Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes
Grant 7,674,888 - Perron , et al. March 9, 2
2010-03-09
HXHV virus, nucleic material, peptide material and uses
Grant 7,479,386 - Chemin , et al. January 20, 2
2009-01-20
Viral Material And Nucleotide Fragments Associated With Multiple Sclerosis, For Diagnostic, Prophylactic And Therapeutic Purposes
App 20070117189 - PERRON; Herve ;   et al.
2007-05-24
Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes
App 20070031452 - Perron; Herve ;   et al.
2007-02-08
Mutated env gene, mutated env glycoprotein and the use thereof
App 20050065320 - Bedin, Frederic ;   et al.
2005-03-24
Hxhv virus, nucleic material, peptide material and uses
App 20050037336 - Chemin, Isabelle ;   et al.
2005-02-17
Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes
App 20030198647 - Perron, Herve ;   et al.
2003-10-23
Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purpose
App 20030186391 - Perron, Herve ;   et al.
2003-10-02
Isolated Nucleotide Sequences Associated With Multiple Sclerosis Or Rheumatoid Arthritis And A Process Of Detecting
App 20030039664 - PERRON, HERVE ;   et al.
2003-02-27
Cell lines and viral isolates associated with multiple sclerosis
Grant 6,342,383 - Perron , et al. January 29, 2
2002-01-29
Isolated nucleotide sequences associated with Multiple sclerosis
Grant 6,001,987 - Perron , et al. December 14, 1
1999-12-14
Detection of MSRV1 virus and MSRV2 pathogen and/or infective agent associated with multiple sclerosis, by nucleic acid hybridization
Grant 5,800,980 - Perron , et al. September 1, 1
1998-09-01

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed